- In December 2024, Dewpoint Therapeutics Inc. has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance its novel TDP-43 small molecule condensate modulator for amyotrophic lateral sclerosis (ALS), effective December 1, 2024. This collaboration will help Dewpoint Therapeutics by enhancing its research capabilities, accelerating the development of its ALS treatment, and expanding its presence in the neurological therapeutics market
- In November 2024, Ascend Advanced Therapies has teamed up with EW Healthcare Partners to strengthen its presence and expand its infrastructure in the U.S. This partnership will help Ascend by enhancing its market reach, boosting operational capabilities, and supporting continued growth in gene-to-GMP development
- In November 2024, Bharath Advanced Therapeutics (BAT) and the Federation of Asian Biotech Associations (FABA) are hosting Cancer NEXT 2024, an oncology research conference aimed at advancing cancer treatment through collaboration and innovation. This event will help BAT by enhancing its visibility in the oncology sector, fostering key partnerships, and showcasing its leadership in cancer research
- In November 2024, NextCell Pharma AB, the parent company of QVance, supports QVance’s partnership with Royale International to enhance the supply chain for cell and gene therapies across Europe by leveraging Royale International’s logistics expertise. This collaboration will help QVance by improving its distribution capabilities, ensuring efficient delivery, and expanding its reach in the European cell and gene therapy market
- In October 2024, Dyno Therapeutics, Inc. has announced its second research collaboration with Roche to develop advanced AAV vectors for gene therapies targeting neurological diseases. This partnership will help Dyno Therapeutics by enhancing its AI-driven gene delivery technologies and accelerating the development of innovative therapies for neurological conditions
